转移性肾细胞癌-话题@MedSci

#转移性肾细胞癌#

54篇内容 | 2583人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1420318, encodeId=5557142031881, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=ASCO GU 2021: 转移性肾细胞癌一线采用免疫治疗效果如何？, objectType=article, longId=207195, objectId=8fad20e19548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fad20e19548, replyNumber=0, likeNumber=0, createdTime=2021-02-18, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fad20e19548, moduleTitle=ASCO GU 2021: 转移性肾细胞癌一线采用免疫治疗效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fad20e19548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420317, encodeId=0eab142031eb3, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Eur Urol Oncol：选择转移性肾细胞癌患者中进行减瘤性肾切除术的更佳候选者的一种新的风险评分开发, objectType=article, longId=205986, objectId=3fd020598612, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fd020598612, replyNumber=0, likeNumber=125, createdTime=2021-01-23, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fd020598612, moduleTitle=Eur Urol Oncol：选择转移性肾细胞癌患者中进行减瘤性肾切除术的更佳候选者的一种新的风险评分开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fd020598612)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420316, encodeId=9c1314203164a, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Radiology：转移性肾细胞癌化疗后有没有效如何看？, objectType=article, longId=204280, objectId=cf0020428046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf0020428046, replyNumber=0, likeNumber=82, createdTime=2020-12-09, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf0020428046, moduleTitle=Radiology：转移性肾细胞癌化疗后有没有效如何看？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf0020428046)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420315, encodeId=8794142031533, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Sci Rep：一线阿西替尼治疗纺锤组织学转移性肾细胞癌效果较差, objectType=article, longId=203908, objectId=cbca2039086d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbca2039086d, replyNumber=0, likeNumber=0, createdTime=2020-12-01, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbca2039086d, moduleTitle=Sci Rep：一线阿西替尼治疗纺锤组织学转移性肾细胞癌效果较差, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbca2039086d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420314, encodeId=070514203148b, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=树突状细胞疗法ilixadencel获得FDA授予的再生医学高级疗法称号，用于治疗转移性肾细胞癌, objectType=article, longId=193622, objectId=7ffb19362230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ffb19362230, replyNumber=0, likeNumber=61, createdTime=2020-05-08, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ffb19362230, moduleTitle=树突状细胞疗法ilixadencel获得FDA授予的再生医学高级疗法称号，用于治疗转移性肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ffb19362230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420313, encodeId=bb6b1420313a3, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=日本批准CABOMETYX（cabozantinib）治疗无法切除的或转移性肾细胞癌, objectType=article, longId=190852, objectId=502a190852b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=502a190852b7, replyNumber=0, likeNumber=80, createdTime=2020-03-27, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=502a190852b7, moduleTitle=日本批准CABOMETYX（cabozantinib）治疗无法切除的或转移性肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=502a190852b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420312, encodeId=060c1420312df, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=FDA批准CMN-001治疗晚期转移性肾细胞癌的IND, objectType=article, longId=188492, objectId=cfd518849273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfd518849273, replyNumber=0, likeNumber=75, createdTime=2020-02-22, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfd518849273, moduleTitle=FDA批准CMN-001治疗晚期转移性肾细胞癌的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfd518849273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420311, encodeId=8cb6142031112, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％, objectType=article, longId=188280, objectId=62191882804d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62191882804d, replyNumber=0, likeNumber=67, createdTime=2020-02-19, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62191882804d, moduleTitle=CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62191882804d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420310, encodeId=bee31420310a4, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Opdivo联合Yervoy用于先前未治疗的晚期或转移性肾细胞癌患者，在42个月的随访中证明了持续的生存益处, objectType=article, longId=188272, objectId=6dff1882e2d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dff1882e2d8, replyNumber=0, likeNumber=71, createdTime=2020-02-19, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dff1882e2d8, moduleTitle=Opdivo联合Yervoy用于先前未治疗的晚期或转移性肾细胞癌患者，在42个月的随访中证明了持续的生存益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dff1882e2d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420309, encodeId=2d3514203095b, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Lancet oncol：Tivozanib治疗转移性肾细胞癌！, objectType=article, longId=184622, objectId=33e318462202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33e318462202, replyNumber=0, likeNumber=93, createdTime=2019-12-13, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33e318462202, moduleTitle=Lancet oncol：Tivozanib治疗转移性肾细胞癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33e318462202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420308, encodeId=b43e1420308ad, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Clin Genitourin Cancer：叶酸可减少转移性肾细胞癌患者的粘膜炎, objectType=article, longId=178327, objectId=09a01e83274b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09a01e83274b, replyNumber=0, likeNumber=79, createdTime=2019-08-30, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09a01e83274b, moduleTitle=Clin Genitourin Cancer：叶酸可减少转移性肾细胞癌患者的粘膜炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09a01e83274b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420307, encodeId=0090142030e62, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=2019 KCRNC共识声明：转移性肾细胞癌患者减瘤性肾切除术的作用, objectType=article, longId=169061, objectId=2e48169061ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e48169061ff, replyNumber=0, likeNumber=75, createdTime=2019-06-25, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e48169061ff, moduleTitle=2019 KCRNC共识声明：转移性肾细胞癌患者减瘤性肾切除术的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e48169061ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420306, encodeId=41e6142030670, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Sci Rep：转移性肾细胞癌负担和位点可作为一线药物舒尼替尼治疗效果的预测因子, objectType=article, longId=167522, objectId=d9d516e522d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9d516e522d8, replyNumber=0, likeNumber=101, createdTime=2019-06-04, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9d516e522d8, moduleTitle=Sci Rep：转移性肾细胞癌负担和位点可作为一线药物舒尼替尼治疗效果的预测因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9d516e522d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420305, encodeId=d53e142030508, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=J Hematol Oncol：未经治的转移性肾细胞癌患者使用帕唑帕尼和舒尼替尼安全吗？, objectType=article, longId=155658, objectId=3144155658f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3144155658f9, replyNumber=0, likeNumber=61, createdTime=2018-12-14, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3144155658f9, moduleTitle=J Hematol Oncol：未经治的转移性肾细胞癌患者使用帕唑帕尼和舒尼替尼安全吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3144155658f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420304, encodeId=fd9d142030425, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=2018 CUA指南：非转移性肾细胞癌患者治疗后随访, objectType=article, longId=147550, objectId=562e14e55099, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=562e14e55099, replyNumber=0, likeNumber=61, createdTime=2018-08-29, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=562e14e55099, moduleTitle=2018 CUA指南：非转移性肾细胞癌患者治疗后随访, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=562e14e55099)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420303, encodeId=2e93142030313, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=NEJM：转移性肾细胞癌患者单独使用舒尼替尼或肾切除术后使用舒尼替尼效果分析, objectType=article, longId=145727, objectId=de84145e276d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de84145e276d, replyNumber=0, likeNumber=96, createdTime=2018-08-04, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de84145e276d, moduleTitle=NEJM：转移性肾细胞癌患者单独使用舒尼替尼或肾切除术后使用舒尼替尼效果分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de84145e276d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420302, encodeId=7b54142030245, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=2018 SIOG意见书：老年转移性肾细胞癌患者的管理, objectType=article, longId=141221, objectId=78d314122182, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78d314122182, replyNumber=0, likeNumber=77, createdTime=2018-06-22, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78d314122182, moduleTitle=2018 SIOG意见书：老年转移性肾细胞癌患者的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78d314122182)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420301, encodeId=b6a614203014f, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=NEJM：转移性肾细胞癌患者单纯或肾切除术后舒尼替尼疗效研究, objectType=article, longId=139942, objectId=3e67139942bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e67139942bc, replyNumber=0, likeNumber=95, createdTime=2018-06-06, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e67139942bc, moduleTitle=NEJM：转移性肾细胞癌患者单纯或肾切除术后舒尼替尼疗效研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e67139942bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420300, encodeId=157714203004a, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Brit J Cancer：转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究, objectType=article, longId=139220, objectId=46ac139220d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ac139220d5, replyNumber=0, likeNumber=63, createdTime=2018-05-28, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ac139220d5, moduleTitle=Brit J Cancer：转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46ac139220d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420299, encodeId=a628142029957, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案（Alliance A031203 CABOSUN随机试验）：总生存期和无进展生存, objectType=article, longId=136870, objectId=65ff1368e0d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65ff1368e0d9, replyNumber=0, likeNumber=106, createdTime=2018-05-01, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65ff1368e0d9, moduleTitle=Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案（Alliance A031203 CABOSUN随机试验）：总生存期和无进展生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65ff1368e0d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性肾细胞癌

2020-05-29

zhangyxzsh

#转移性肾细胞癌#

ASCO GU 2021: 转移性肾细胞癌一线采用免疫治疗效果如何？

2021-02-18

zhangyxzsh

#转移性肾细胞癌#

Eur Urol Oncol：选择转移性肾细胞癌患者中进行减瘤性肾切除术的更佳候选者的一种新的风险评分开发

2021-01-23

zhangyxzsh

#转移性肾细胞癌#

Radiology：转移性肾细胞癌化疗后有没有效如何看？

2020-12-09

zhangyxzsh

#转移性肾细胞癌#

Sci Rep：一线阿西替尼治疗纺锤组织学转移性肾细胞癌效果较差

2020-12-01

zhangyxzsh

#转移性肾细胞癌#

树突状细胞疗法ilixadencel获得FDA授予的再生医学高级疗法称号，用于治疗转移性肾细胞癌

2020-05-08

zhangyxzsh

#转移性肾细胞癌#

日本批准CABOMETYX（cabozantinib）治疗无法切除的或转移性肾细胞癌

2020-03-27

zhangyxzsh

#转移性肾细胞癌#

FDA批准CMN-001治疗晚期转移性肾细胞癌的IND

2020-02-22

zhangyxzsh

#转移性肾细胞癌#

CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％

2020-02-19

zhangyxzsh

#转移性肾细胞癌#

Opdivo联合Yervoy用于先前未治疗的晚期或转移性肾细胞癌患者，在42个月的随访中证明了持续的生存益处

2020-02-19

zhangyxzsh

#转移性肾细胞癌#

Lancet oncol：Tivozanib治疗转移性肾细胞癌！

2019-12-13

zhangyxzsh

#转移性肾细胞癌#

Clin Genitourin Cancer：叶酸可减少转移性肾细胞癌患者的粘膜炎

2019-08-30

zhangyxzsh

#转移性肾细胞癌#

2019 KCRNC共识声明：转移性肾细胞癌患者减瘤性肾切除术的作用

2019-06-25

zhangyxzsh

#转移性肾细胞癌#

Sci Rep：转移性肾细胞癌负担和位点可作为一线药物舒尼替尼治疗效果的预测因子

2019-06-04

zhangyxzsh

#转移性肾细胞癌#

J Hematol Oncol：未经治的转移性肾细胞癌患者使用帕唑帕尼和舒尼替尼安全吗？

2018-12-14

zhangyxzsh

#转移性肾细胞癌#

2018 CUA指南：非转移性肾细胞癌患者治疗后随访

2018-08-29

zhangyxzsh

#转移性肾细胞癌#

NEJM：转移性肾细胞癌患者单独使用舒尼替尼或肾切除术后使用舒尼替尼效果分析

2018-08-04

zhangyxzsh

#转移性肾细胞癌#

2018 SIOG意见书：老年转移性肾细胞癌患者的管理

2018-06-22

zhangyxzsh

#转移性肾细胞癌#

NEJM：转移性肾细胞癌患者单纯或肾切除术后舒尼替尼疗效研究

2018-06-06

zhangyxzsh

#转移性肾细胞癌#

Brit J Cancer：转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究

2018-05-28

zhangyxzsh

#转移性肾细胞癌#

Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案（Alliance A031203 CABOSUN随机试验）：总生存期和无进展生存

2018-05-01